Alzheimer's disease

New gene therapies in clinical trials seek to treat Alzheimer’s disease and heal the brain with a dose of helpful genetic material.

By watching brain organoids develop, researchers observed surprising abnormalities caused by mutations in a gene related to early-onset Alzheimer’s disease.

Young blood rejuvenates aging organs in rodents. Researchers are studying the potential to use young blood-based treatments in aging humans too.

Activating specific neurons using light helped scientists establish a causal link between improved sleep and diminished signs of Alzheimer’s disease in mice.

Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery. 

A small molecule called ALGERNON2 improved health outcomes in mouse models of neurodegenerative diseases by activating antioxidant pathways in astrocytes.

A dementia-associated tau mutation promotes unusual clustering of Fyn, a protein important for learning and memory.

A collaboration of nephrologists and biochemists created the first structure of “megalin,” a critical protein in kidney and brain disorders.

By analyzing the changing genomes of short- and long-lived rockfish, scientists identified a new set of genes that might alter lifespan.

Drugs that target senescent cells could one day treat frailty, Alzheimer’s disease, or cancer.